BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders

January 3, 2024

https://www.globenewswire.com/news-release/2024/01/03/2803155/0/en/BioCardia-Biotherapeutic-Delivery-and-Morph-Access-Innovations-Business-Development-Update-for-Shareholders.html

SUNNYVALE, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. (Nasdaq:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, issues the following letter to shareholders:

Related news for (BCDA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.

BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders

Related news for (BCDA)

Follow Us on Social Media

Sign Up for Our Newsletter

Related news for (BCDA)

Power Hour Pulse: Spider Silk Surge and Biotech Beats Drive Afternoon Frenzy – These Microcaps Could Explode into Close

From Web3 to Quantum: Small-Cap Innovators OFAL, SPRC, XXII Lead Market Movers as XHLD Builds Visibility

Growth Bets Drive Market Pulse Ahead of Earnings

Spider Silk, Splicing & Strategic Capital: Biotech and Innovation Dominate the Morning Tape

Ad Tech Shakes, AI Stakes & Penny Stock Quakes

Follow Us on Social Media

Sign Up for Our Newsletter